Plain-English translation of NCT06925321 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new antifungal medication called fosmanogepix to treat serious mold infections that have invaded the body—infections caused by resistant molds that are difficult to treat. The study will compare this medication to standard antifungal treatments in some patients, and offer the medication to patients whose previous antifungal treatments have failed or caused side effects. Researchers want to know if this treatment is safe and effective at improving survival rates.
Serious invasive mold infections are life-threatening, especially when caused by rare or drug-resistant fungi, and patients often run out of effective treatment options. This trial exists to see whether this new medication can help save lives when standard antifungal drugs don't work or are poorly tolerated.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will either receive the new medication or standard antifungal treatment (depending on which group you're assigned to), given as an IV infusion or oral medication. The main treatment period lasts about 12 weeks, though it can be extended up to 6 months if needed, followed by a follow-up period. Your total involvement in the study will be approximately 8 months, during which you'll have regular visits to monitor how well the treatment is working and check for side effects.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States